EP1985311A4 - Agent pour cibler un médicament sur un neurone cérébral - Google Patents

Agent pour cibler un médicament sur un neurone cérébral

Info

Publication number
EP1985311A4
EP1985311A4 EP07707746A EP07707746A EP1985311A4 EP 1985311 A4 EP1985311 A4 EP 1985311A4 EP 07707746 A EP07707746 A EP 07707746A EP 07707746 A EP07707746 A EP 07707746A EP 1985311 A4 EP1985311 A4 EP 1985311A4
Authority
EP
European Patent Office
Prior art keywords
agent
targeting drug
cerebral neuron
neuron
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07707746A
Other languages
German (de)
English (en)
Other versions
EP1985311A1 (fr
Inventor
Satoshi Kuchiiwa
Toshiko Kuchiiwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagoshima University NUC
Original Assignee
Kagoshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagoshima University NUC filed Critical Kagoshima University NUC
Publication of EP1985311A1 publication Critical patent/EP1985311A1/fr
Publication of EP1985311A4 publication Critical patent/EP1985311A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/558—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a chemiluminescent acceptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP07707746A 2006-01-24 2007-01-24 Agent pour cibler un médicament sur un neurone cérébral Withdrawn EP1985311A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006015320 2006-01-24
PCT/JP2007/051528 WO2007086587A1 (fr) 2006-01-24 2007-01-24 Agent pour cibler un médicament sur un neurone cérébral

Publications (2)

Publication Number Publication Date
EP1985311A1 EP1985311A1 (fr) 2008-10-29
EP1985311A4 true EP1985311A4 (fr) 2011-04-13

Family

ID=38309364

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07707746A Withdrawn EP1985311A4 (fr) 2006-01-24 2007-01-24 Agent pour cibler un médicament sur un neurone cérébral

Country Status (4)

Country Link
US (1) US20110077204A1 (fr)
EP (1) EP1985311A4 (fr)
JP (1) JP4945766B2 (fr)
WO (1) WO2007086587A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730328C (fr) 2008-09-03 2015-03-31 Board Of Trustees Of Michigan State University Enterotoxine thermostable d'escherichia coli immunogene
US9649381B2 (en) 2013-11-06 2017-05-16 Wayne State University Transporter protein-coupled nanodevices for targeted drug delivery
JP2017534598A (ja) * 2014-09-30 2017-11-24 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 神経系疾患を治療する標的療法のための汎用的なプラットフォーム

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091387A2 (fr) * 2002-04-26 2003-11-06 Ferguson Ian A Administration non invasive de polypeptides a travers la barriere hemato-encephalique et selection in vivo de ligands endocytotiques
WO2004021992A2 (fr) * 2002-09-06 2004-03-18 The General Hospital Corporation Administration de composes therapeutiques au cerveau et a la moelle epiniere
WO2005094497A2 (fr) * 2004-03-24 2005-10-13 Emory University Administration systemique d'agents therapeutiques au systeme nerveux central

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007322A (es) * 2003-01-06 2006-02-17 Angiochem Inc Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
US20050027110A1 (en) * 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091387A2 (fr) * 2002-04-26 2003-11-06 Ferguson Ian A Administration non invasive de polypeptides a travers la barriere hemato-encephalique et selection in vivo de ligands endocytotiques
WO2004021992A2 (fr) * 2002-09-06 2004-03-18 The General Hospital Corporation Administration de composes therapeutiques au cerveau et a la moelle epiniere
WO2005094497A2 (fr) * 2004-03-24 2005-10-13 Emory University Administration systemique d'agents therapeutiques au systeme nerveux central

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GAILLARD P J ET AL: "Targeted delivery across the blood-brain barrier", EXPERT OPINION ON DRUG DELIVERY, INFORMA HEALTHCARE, GB, vol. 2, no. 2, 1 January 2005 (2005-01-01), pages 299 - 309, XP008086757, ISSN: 1742-5247, DOI: 10.1517/17425247.2.2.299 *
LARSEN ET AL: "Origin of projections from the midbrain raphe nuclei to the hypothalamic paraventricular nucleus in the rat: A combined retrograde and anterograde tracing study", NEUROSCIENCE, NEW YORK, NY, US, vol. 70, no. 4, 1 February 1996 (1996-02-01), pages 963 - 988, XP022264695, ISSN: 0306-4522, DOI: 10.1016/0306-4522(95)00415-7 *
OKADO N ET AL: "Retrograde neuronal labelling by E. coli enterotoxin subunit B", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 120, no. 2, 11 December 1990 (1990-12-11), pages 263 - 266, XP024343999, ISSN: 0304-3940, [retrieved on 19901211], DOI: 10.1016/0304-3940(90)90055-E *
PESECHNIK V ET AL: "Macromolecular drug delivery to the CNS with protein carriers", EXPERT OPINION ON INVESTIGATIONAL DRUGS 1996 GB, vol. 5, no. 10, 1996, pages 1255 - 1276, XP009145336, ISSN: 1354-3784 *
See also references of WO2007086587A1 *

Also Published As

Publication number Publication date
JP4945766B2 (ja) 2012-06-06
EP1985311A1 (fr) 2008-10-29
JPWO2007086587A1 (ja) 2009-06-25
WO2007086587A1 (fr) 2007-08-02
US20110077204A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
EP2119444A4 (fr) Agent thérapeutique pour la douleur
IL192565A0 (en) Medicament for topical use
GB0609492D0 (en) Therapeutic agents
GB0608928D0 (en) Therapeutic agents
IL207892A0 (en) Agent for treating disease
HK1151533A1 (zh) 種治療疾病的試劑
GB0601962D0 (en) Therapeutic agents
IL207891A0 (en) Agent for treating disease
EP2060264A4 (fr) Agent pour traiter des maladies oculaires
PT2280717T (pt) Agente terapêutico para doenças anaeróbias
GB0611152D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
GB0625783D0 (en) Medicament
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
EP1985311A4 (fr) Agent pour cibler un médicament sur un neurone cérébral
EP2517698A4 (fr) Agent pour traiter la maladie de parkinson
EP2123295A4 (fr) Agent thérapeutique contre la pneumonie interstitielle
GB0615064D0 (en) Medicament
EP2127658A4 (fr) Agent thérapeutique pour la maladie de ménière
EP2305629A4 (fr) Agent thérapeutique pour la maladie d'alzheimer
EP2140876A4 (fr) Agent thérapeutique comprenant de la vasohibine
GB0608996D0 (en) Drug counter
EP2210878A4 (fr) Agent thérapeutique pour une maladie induite par le trpv-1
HK1147211A1 (en) An agent for reducing a side effect of an anticancer drug

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB

A4 Supplementary search report drawn up and despatched

Effective date: 20110311

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111011